

CB2 Insights

11:40 19 Sep 2019

Buds & Duds: Cannabis stocks trend lower; CB2 Insights rises on new UK deal

Cannabis stocks trended lower on Thursday across the US and Canada.

The North American Marijuana Index, which tracks the top cannabis stocks in both countries, lost 2.3% to hit 173.9 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF fell 1.1% to C\$14.26, while the OTCQX Cannabis Index inched 0.2% higher to 646.7 points.

Buds

Medical cannabis data group CB2 Insights Inc (CSE:CBII) (OTCMKTS:CBIIIF) saw its shares jump after revealing it had increased its market presence in the UK.

The company told investors Thursday it will license its technology to MyAccess Clinics (MAC) to manage their patient data. The group operates multiple clinics in the UK and is focused on providing care for patients with unmet needs, which licensed medicines have failed to address.

Shares of the Toronto-based cannabis company sailed 7.7% higher on the news to rest at C\$0.14 in Canada and were 5% higher on OTC markets at US\$0.11.

Also moving higher was Weekend Unlimited Inc (CSE:POT) (OTCMKTS:WKULF) after announcing that it is entering the hemp-derived CBD space with its WKND! Wellness product line, which will soon be available online and for retail sales in the United States.

Its shares jumped 6.7% to C\$0.08 in Canada and 12.7% on OTC markets at US\$0.06.

Harvest One Cannabis Inc (CVE:HVT) (OTCMKTS:HRVOF) also saw a nice bump on Thursday on news that its portfolio company Burb has been awarded its first two retail cannabis licenses in British Columbia.

Shares of Harvest One rose 3.1% to C\$0.50 in Toronto and traded down 0.2% on OTC markets at US\$0.36.

Duds

Shares of multistate operator Cronos Group Inc (NASDAQ:CRON) (TSE:CRON) fell on the day after announcing a new manufacturing agreement with MediPharm Labs Corp (TSE:LABS) (OTCMKTS:MEDIF).

The two-year agreement sees MediPharm providing filling of high-quality formulated concentrate, labelling and packaging services to Cronos.

Cronos shares were down 4.7% in Toronto at C\$13.87 and 4.8% in New York at US\$10.43.

Cannabis analytics and software company Lift & Co Corp (CVE:LIFT) bled on Thursday, dropping almost 19% in

Price: 0.105

Market Cap: \$8.4 m

1 Year Share Price Graph



Share Information

Code: CBII

Listing: CSE

52 week	High	Low
	0.5	0.055

Sector: Cannabis

Website: cb2insights.com

Company Synopsis:

Our mission is to deliver the industry's most comprehensive, data-driven software and services - transforming the way the global cannabis industry evolves through actionable insights.

action@proactiveinvestors.com

Canada at C\$0.15. The company closed a C\$3.5 million private placement eight days ago.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CB2 Insights named herein, including the promotion by the Company of CB2 Insights in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).